Symptomatic pulmonary embolism following hip fracture: A nationwide study

Thromb Res. 2018 Dec:172:120-127. doi: 10.1016/j.thromres.2018.10.014. Epub 2018 Oct 18.

Abstract

Introduction: This study evaluated the incidence of symptomatic pulmonary embolism (PE), subsequent mortality, risk factors, and the effects of pharmacological thromboprophylactic intervention following hip fracture surgery in Taiwan.

Materials and methods: A nationwide study was conducted from February 2004 to September 2013. Hip fracture patients were placed into two groups: without symptomatic PE (control group) and with symptomatic PE (PE group). We analyzed the incidence of and risk factors for symptomatic PE, post-operative mortality rate, and effects of pharmacological thromboprophylactic intervention.

Results: We identified 165,748 hip fracture patients. The 3-month cumulative incidence of post-operative symptomatic PE was 0.24% (n = 392). The cumulative 1-, 3-, and 6-month mortality rates were significantly higher in the PE group (16.1%, 23.0%, and 28.6%, respectively) than in the controls (3.3%, 6.7%, and 10.2%, respectively). Increased risk of post-operative symptomatic PE was associated with prior history of PE (adjusted odds ratio [OR], 40.00; 95% CI, 24.75-64.67; P < 0.001), female sex (adjusted OR, 1.33; 95% CI, 1.07-1.65; P = 0.009), older age (>75 years) (adjusted OR, 1.51; 95% CI, 1.20-1.91; P < 0.001), and hemiarthroplasty (adjusted OR, 1.23; 95% CI, 1.01-1.51; P < 0.043). Pharmacological thromboprophylaxis significantly reduced the incidence of post-operative PE (adjusted hazard ratio, 4.54; 95% CI, 2.08-9.88; P < 0.001).

Conclusions: The incidence of symptomatic PE after hip fracture surgery was not low in Asian patients, and PE significantly decreased patient survival rates. Some groups were at higher risk for PE; in these instances, thromboprophylaxis, prompt diagnosis, and subsequent intervention are advised.

Keywords: Hip fracture; Mortality; Propensity score; Pulmonary embolism; Risk factor.

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Anticoagulants / therapeutic use
  • Arthroplasty, Replacement, Hip / adverse effects*
  • Arthroplasty, Replacement, Hip / mortality
  • Female
  • Hip Fractures / mortality
  • Hip Fractures / surgery*
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Odds Ratio
  • Platelet Aggregation Inhibitors / therapeutic use
  • Postoperative Complications / etiology*
  • Postoperative Complications / mortality
  • Postoperative Complications / prevention & control
  • Proportional Hazards Models
  • Pulmonary Embolism / etiology*
  • Pulmonary Embolism / mortality
  • Pulmonary Embolism / prevention & control
  • Retrospective Studies
  • Risk Factors
  • Sex Factors
  • Survival Rate
  • Taiwan / epidemiology

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors